UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

Liu, Shiqin; Chai, Timothy; Garcia-Marques, Fernando; Yin, Qingqing; Hsu, En-Chi; Shen, Michelle; Shaw Toland, Angus Martin; Bermudez, Abel; Hartono, Alifiani B.; Massey, Christopher F.; Lee, Chung S.; Zheng, Liwei; Baron, Maya; Denning, Caden J.; Aslan, Merve; Nguyen, Holly M.; Nolley, Rosalie; Zoubeidi, Amina; Das, Millie; Kunder, Christian A.; Howitt, Brooke E.; Soh, H. Tom; Weissman, Irving L.; Liss, Michael A.; Chin, Arnold I.; Brooks, James D.; Corey, Eva; Pitteri, Sharon J.; Huang, Jiaoti; Stoyanova, Tanya

doi:10.1016/j.xcrm.2023.101381

Cited by 9 publications

(1 citation statement)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research on targeted therapy for NEC of the genitourinary system is relatively scarce. Some studies have proposed ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, as a therapeutic target for it [ 23 ]. Additionally, in NEC of other systems such as the pancreas and thyroid, RET has been regarded as an effective predictive marker, and RET-targeting tyrosine kinase inhibitors are considered to have potential therapeutic effects [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study

Niu,

Sun,

Fan

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Neuroendocrine carcinoma (NEC) is a rare yet potentially perilous neoplasm. The objective of this study was to develop prognostic models for the survival of NEC patients in the genitourinary system and subsequently validate these models. A total of 7125 neuroendocrine neoplasm (NEN) patients were extracted. Comparison of survival in patients with different types of NEN before and after propensity score-matching (PSM). A total of 3057 patients with NEC, whose information was complete, were extracted. The NEC influencing factors were chosen through the utilization of the least absolute shrinkage and selection operator regression model (LASSO) and the Fine & Gary model (FGM). Furthermore, nomograms were built. To validate the accuracy of the prediction, the efficiency was verified using bootstrap self-sampling techniques and receiver operating characteristic curves. LASSO and FGM were utilized to construct three models. Confirmation of validation was achieved by conducting analyses of the area under the curve and decision curve. Moreover, the FGS (DSS analysis using FGM) model produced higher net benefits. To maximize the advantages for patients, the FGS model disregarded the influence of additional occurrences. Patients are expected to experience advantages in terms of treatment options and survival assessment through the utilization of these models.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study

Niu,

Sun,

Fan

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets

Jiang,

Han,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

Neuroendocrine transdifferentiation (NEtD), also commonly referred to as lineage plasticity, emerges as an acquired resistance mechanism to molecular targeted therapies in multiple cancer types, predominately occurs in metastatic epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors and metastatic castration‐resistant prostate cancer treated with androgen receptor targeting therapies. NEtD tumors are the lethal cancer histologic subtype with unfavorable prognosis and limited treatment. A comprehensive understanding of molecular mechanism underlying targeted‐induced plasticity could greatly facilitate the development of novel therapies. In the past few years, increasingly elegant studies indicated that NEtD tumors share key the convergent genomic and phenotypic characteristics irrespective of their site of origin, but also embrace distinct change and function of molecular mechanisms. In this review, we provide a comprehensive overview of the current understanding of molecular mechanism in regulating the NEtD, including genetic alterations, DNA methylation, histone modifications, dysregulated noncoding RNA, lineage‐specific transcription factors regulation, and other proteomic alterations. We also provide the current management of targeted therapies in clinical and preclinical practice.

show abstract

The role of cell cycle-related genes in the tumorigenesis of adrenal and thyroid neuroendocrine tumors

Filipovich,

Gorodkova,

Shcherbakova

et al. 2025

Heliyon

View full text Add to dashboard Cite

UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

Cited by 9 publications

References 82 publications

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets

The role of cell cycle-related genes in the tumorigenesis of adrenal and thyroid neuroendocrine tumors

Contact Info

Product

Resources

About